Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 1/20 | 0.50 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.50 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.50 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.50 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 3/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.45 |
| ▸ | MDM4 | O15151 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17707302 | 1.00 | GRIN2D (0.50) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL12270170 | 0.94 | ALDH1A1 (0.50) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL22328175 | 0.87 | NPC1 (0.53) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL28416120 | 0.85 | GRIN2D (0.46) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL14176745 | 0.84 | NPC1 (0.63) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL22328176 | 0.84 | HDAC4 (0.44) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL21887189 | 0.82 | RXRA (0.54) | TDP1ALDH1A1MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL28389086 | 0.82 | GRIN2D (0.47) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL8283388 | 0.82 | GRIN2D (0.47) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL2889331 | 0.81 | MIF (0.48) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3215481-B1 | METHOD FOR PRODUCING BIPHENYLAMINES FROM AZOBENZOLES BY RUTHENIUM CATALYSIS | BAYER CROPSCIENCE AG (DE) | 2018-12-26 | — | — | EP | disclosed |
| US-10011557-B2 | Method for producing biphenylamines from azobenzenes by ruthenium catalysis | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2018-07-03 | — | — | US | disclosed |
| US-20170334832-A1 | METHOD FOR PRODUCING BIPHENYLAMINES FROM AZOBENZENES BY RUTHENIUM CATALYSIS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2017-11-23 | — | — | US | disclosed |
| EP-3015452-A1 | Method for the production of biphenylamines from azobenzenes using ruthenium catalysis | Bayer CropScience AG (DE) | 2016-05-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10011557-B2 | Method for producing biphenylamines from azobenzenes by ruthenium catalysis | AHR, CYP4B1, DDT | GRIN2D 3807/4885GRIN3B 3335/4885GRIN1 3980/4885 |
| US-20170334832-A1 | METHOD FOR PRODUCING BIPHENYLAMINES FROM AZOBENZENES BY RUTHENIUM CATALYSIS | AHR, CYP4B1, CYP1A1 | GRIN2D 3539/4885GRIN3B 3408/4885GRIN1 3937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.